Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Tools & Technology › Sequencing › Guardant Health Liquid Biopsy Test Improves Gastrointestinal Cancer Clinical Trial Enrollment

Guardant Health Liquid Biopsy Test Improves Gastrointestinal Cancer Clinical Trial Enrollment

Oct 05, 2020
|
staff reporter

NEW YORK – Analyzing circulating tumor DNA can both speed up and boost the enrollment of cancer patients into clinical trials, according to a new study focusing on gastrointestinal cancer. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Featured Webinar

PIK3CA Mutations in Advanced Breast Cancer: The Vital Role of Tissue and Plasma Companion Diagnostics

Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

What's Popular?

In Cancer

  1. FDA Accepts Invitae Premarket Approval Submission for Stratafide Companion Diagnostic

  2. Genentech, OneOncology Partner on Genomic Profiling for Personalized Cancer Care

  3. SEngine Precision Medicine IDs Potential Ovarian Cancer Treatment Combos Using Organoid Approach

    Premium

  4. Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program

  5. Tumor, Germline Testing of Cancer Patients Can Give Discordant Results

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.